99mTc(V)-DMSA SPECT for the assessment of disease activity in Graves' ophthalmopathy

Nuclear Medicine Communications

Volumn 28, Issue 10, 2007, Pages 775-781

  Reyhan, Mehmet ^a   Toygar, Okan ^a   Sukan, Aysun ^a   Seydaoglu, Gulsah ^a   Bakiner, Okan S ^a   Aydin, Mehmet ^a   Yapar, A Fuat ^a   Aktas, Ayse ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Graves' disease; Ophthalmopathy

Indexed keywords

SUCCIMER TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLLIMATOR; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG UPTAKE; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; IMAGE RECONSTRUCTION; LOW ENERGY RADIATION; MALE; MEDICAL PARAMETERS; MEDICAL SOCIETY; NOSE CAVITY; ORBIT; RADIATION DETECTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ADULT; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34548297773     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282e7d746     Document Type: Article

References (26)

1. Perros P, Dickinson AJ. Ophthalmopathy. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams and Wilkins; 2005, pp. 474-487.
2. Jameson JL. Endocrinology. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. London: McGraw-Hill; 2001, pp. 2019-2191.
3. Prummel MF. Graves' ophthalmopathy: diagnosis and management. Eur J Nucl Med 2000; 27:373-376.
4. Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocrinol 1999; 140:373-375.
5. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997; 47:9-14.
6. Konuk O, Atasever T, Unal M, Ayvaz G, Yetkin T, Cakir N, et al. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy. Thyroid 2002; 12:603-608.
7. Konuk O, Atasever T, Unal M, Ayvaz G, Yetkin T, Cakir N, et al. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment. Thyroid 2005; 15:358-363.
8. Durak I, Durak H, Ergin M, Yurekli Y, Kaynak S. Somatostatin receptors in the orbits. Clin Nucl Med 1995; 20:237-242.
9. 111In-octreotide. Thyroid 1997; 7:21-29.
10. Kahaly G, Gorges R, Diaz, Hommel G, Bockish A. Indium-111-pentetreotide in Graves' disease. J Nucl Med 1998; 39:533-536.
11. Durak H, Soylev M, Durak I, Degirmenci B, Capa KG, Uysal B. Tc-99m polyclonal human immunoglobulin G imaging in Graves' ophthalmopathy. Clin Nucl Med 2000; 25:704-707.
12. Ortapamuk H, Hosal B, Naldoken S. The role of Tc-99m polyclonal human immunoglobulin G scintigraphy in Graves' ophthalmopathy. Ann Nucl Med 2002; 16:461-465.
13. 99mTc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun 2005; 26:407-414.
14. 99mTc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging 2003; 30:1155-1159.
15. Ercan MT, Gulaldý NC, Unsal IS, Aydin M, Peksoy I, Hascelik Z. Evaluation of Tc-99m(V) DMSA for imaging inflammatory lesions: an experimental study. Ann Nucl Med 1996; 10:419-423.
16. 99mTc-DMSA. Nucl Med Commun 1999; 20:769-773.
17. Szucs-Farkas Z, Toth J, Balazs E, Galuska L, Burman KD, Karanyi Z, et al. Using morphologic parameters of extraocular muscles for diagnosis and follow-up of Graves' ophthalmopathy: diameters, areas, or volumes? Am J Roentgenol 2002; 179:1005-1010.
18. Kahaly GJ. Recent developments in Graves' ophthalmopathy imaging. J Endocrinol Invest 2004; 27:254-258.
19. m dimercaptosuccinic acid, a new tumour-seeking agent. Nucl Med Commun 1988; 9:105-116.
20. Hirano T, Otake H, Shibasaki T, Tamura M, Endo K. Differentiating histologic malignancy of primary brain tumours: pentavalent technetium-99m-DMSA. J Nucl Med 1997; 38:20-26.
21. Lee BF, Chen CJ, Yang CC, Yu HS. Psoas muscle abscess causing fever of unknown origin: the value of Tc-99m (V) DMSA imaging. Clin Nucl Med 1997; 22:789-790.
22. Lee BF, Chiu NT, Chang JK, Liu GC, Yu HS. Technetium-99m(V)-DMSA and gallium-67 in the assessment of bone and joint infection. J Nucl Med 1998; 39:2128-2131.
23. 99mTc(V) DMSA scintigraphy. Radiology 2003; 229:70-74.
24. 99mTc(V) DMSA scintigraphy in the detection and localization of intestinal inflammation: comparison of findings in colonoscopy and biopsy. Radiology 2001; 220:381-385.
25. Nakamoto Y, Sakahara H, Kobayashi H, Saga T, Tsuboyama N, Nakamura T, et al. Technetium-99m (V)-dimercaptosuccinic acid: normal accumulation in the breasts. Eur J Nucl Med 1997; 24:1146-1148.
26. 99mTc(V) DMSA: the pituitary sign. Nucl Med Commun 1990; 11:313-317.